The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The company has to approach the DCGI for approval to commence the trials
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Subscribe To Our Newsletter & Stay Updated
